View in EDS

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

Saved in:

Bibliographic Details
Title:	Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Authors:	Moreau P; University Hospital, Nantes, France philippe.moreau@chu-nantes.fr., Pylypenko H; Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine., Grosicki S; Medical University of Silesia, Katowice, Poland., Karamanesht I; Kiev BMT Center, Kiev, Ukraine., Leleu X; Hopital Huriez, CHRU, Lille, France., Rekhtman G; Khmelnitskiy Regional Hospital, Khmelnitskiy, Ukraine., Masliak Z; SI Institute of Blood Pathology and Transfusion Medicine UAMS, Lviv, Ukraine., Robak P; Medical University of Lodz, Lodz, Poland., Esseltine DL; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Feng H; Janssen Research & Development, LLC, Raritan, NJ, USA., Deraedt W; Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium., van de Velde H; Janssen Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium., Arnulf B; Immuno-hématologie Department, Hôpital Saint-Louis, Paris, France.
Source:	Haematologica [Haematologica] 2015 May; Vol. 100 (5), pp. e207-10. Date of Electronic Publication: 2015 Jan 16.
Publication Type:	Clinical Trial, Phase III; Letter; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1592-8721
DOI:	10.3324/haematol.2014.118182